Holen Sie sich die Stockscreener-App
5.10
3.24%
0.16
Handel nachbörslich:
5.09
-0.010
-0.20%
Niagen Bioscience Inc Aktie (NAGE) Neueste Nachrichten
Niagen Bioscience (NAGE) Valuation Check After Strong 2025 Results And Moderated 2026 Growth Outlook - simplywall.st
Niagen Bioscience Rallies 18% After Hours: Here's Why - Benzinga
Niagen Bioscience Doubles Annual Profit, CEO Signals Acquisition Hunt And GLP-1-Style Expansion— Stock Jumps After-Hours (UPDATED) - Benzinga
Niagen Bioscience Inc (NAGE) Q4 2025 Earnings Call Highlights: S - GuruFocus
Niagen Bioscience (NAGE) Reports Strong Q4 and Ambitious 2026 Pl - GuruFocus
Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income I - PharmiWeb.com
Niagen Bioscience (NAGE) Earnings Transcript - The Globe and Mail
Niagen Bioscience (NAGE) Surges 39% Following Q4 Results and Pos - GuruFocus
Niagen Bioscience Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Niagen Bioscience (NAGE) Tops Q4 Earnings and Revenue Estimates - Yahoo! Finance Canada
Earnings call transcript: Niagen Bioscience’s Q4 2025 revenue grows 16% - Investing.com Nigeria
Niagen Bioscience (NAGE) Surpasses Q4 Revenue Expectations - GuruFocus
Niagen Bioscience Reports Strong 2025 Results, Strategic Shift - TipRanks
Niagen Bioscience Q4 Earnings Assessment - Benzinga
Niagen Bioscience soars 38% on blowout Q4 results - Investing.com South Africa
Niagen Bioscience: Fourth Quarter Financial Overview - Bitget
Niagen Bioscience: Q4 Earnings Snapshot - KVUE
Niagen Bioscience earnings beat by $0.03, revenue topped estimates - Investing.com
Niagen Bioscience announces financial results for fourth quarter and fiscal 2025, ChromaDex Corp. states - Traders Union
Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025 - The Joplin Globe
Niagen Bioscience more than doubles 2025 profit as Tru Niagen sales jump - Stock Titan
Niagen Bioscience, Inc. (NAGE) Stock Analysis: Unveiling a Potential 205% Upside in the Biotech Sector - DirectorsTalk Interviews
EPS Watch: Is Niagen Bioscience Inc a cyclical or defensive stockWeekly Trade Recap & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Niagen Bioscience sells reference standards unit to LGC By Investing.com - Investing.com Canada
Niagen Bioscience to streamline operations with the sale of Chromadex reference standards business to LGC - marketscreener.com
VHG Labs, Inc. acquired ChromaDex's analytical reference standards and services business from Niagen Bioscience, Inc.. - marketscreener.com
Niagen Bioscience sells reference standards unit to LGC - Investing.com
Niagen Bioscience Divests Non-Core Analytical Standards Business - TipRanks
Niagen Bioscience To Streamline Operations With The Sale Of Chromadex Reference Standards Business To LGC - TradingView
Niagen Bioscience sells ChromaDex reference standards business to LGC in all-cash deal - TradingView
Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction - Business Wire
Niagen Bioscience secures patent for IV NAD+ precursor delivery - Investing.com India
Assessing Niagen Bioscience (NAGE) Valuation After Recent Share Price Volatility - simplywall.st
Niagen’s NAD+ Bet Is Paying Off, But The Price Is Steep - Finimize
Niagen Bioscience secures patent for IV NAD+ precursor delivery By Investing.com - Investing.com Australia
ChromaDex Corp. reveals new U.S. patent on intravenous NAD plus precursor methods - Traders Union
Niagen Flat on Patent News - Baystreet.ca
Niagen Bioscience secures new U.S. patent for nicotinamide riboside - marketscreener.com
Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside (NR), Niagen - Business Wire
Aug Wrap: Will Niagen Bioscience Inc outperform its industry peers2025 Market Outlook & Safe Entry Momentum Tips - baoquankhu1.vn
Retail Trends: Can Niagen Bioscience Inc grow without dilutionWeekly Trading Summary & Real-Time Price Movement Reports - baoquankhu1.vn
Niagen Bioscience (NAGE) SVP and General Counsel receives 41,420 stock options - Stock Titan
Niagen Bioscience (NAGE) CFO receives grant of 62,131 employee stock options - Stock Titan
Niagen Bioscience, Inc. (NASDAQ:NAGE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Hillsdale Investment Management Inc. Buys Shares of 320,272 Niagen Bioscience, Inc. $NAGE - MarketBeat
Niagen Bioscience, Inc. (NAGE) Stock Analysis: A 219.84% Potential Upside Awaits Investors - DirectorsTalk Interviews
Q4 Earnings Estimate for NAGE Issued By HC Wainwright - Defense World
Can Niagen Bioscience Inc. deliver consistent EPS growth2025 Growth vs Value & Consistent Profit Trade Alerts - mfd.ru
Can Niagen Bioscience Inc. grow without dilutionQuarterly Trade Summary & Free Reliable Trade Execution Plans - mfd.ru
Niagen Bioscience, Inc. (NAGE) Stock Analysis: A Potential Upside of Over 210% Draws Investor Attention - DirectorsTalk Interviews
Is Niagen Bioscience Inc. a cyclical or defensive stockEarnings Beat & Real-Time Buy Signal Alerts - mfd.ru
How is Niagen Bioscience Inc. managing supply chain issuesQuarterly Portfolio Report & Low Drawdown Momentum Trade Ideas - mfd.ru
Can Niagen Bioscience Inc be recession proofJuly 2025 Drop Watch & Accurate Buy Signal Notifications - baoquankhu1.vn
Does BNTX outperform in volatile marketsJuly 2025 Chart Watch & High Accuracy Swing Trade Signals - baoquankhu1.vn
Niagen Bioscience Sponsors Inaugural NAD for Health Conference - intellectia.ai
Niagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Conference Hosted by the University of Copenhagen - Business Wire
Inside Copenhagen’s new NAD conference on aging and metabolism - Stock Titan
Does Niagen Bioscience (NAGE) Still Hold a Defensible NAD+ Moat Ahead of Its 2025 Earnings Call? - simplywall.st
Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026 - The National Law Review
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):